ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Breast Cancer Plan Issues Its First RFA, Other Initiatives To Be Announced Soon

April 14, 1995

SBRT Delivers Higher Overall Survival Rates Compared to Conventional Radiation Therapy

November 30, 2012

NCI To Seek Proposals For Less Invasive Detection, Diagnosis, Treatment Technologies

July 3, 1998

Nexavar Improves PFS In Phase III Trial

January 25, 2013

NCI Seeks Changes In CIS Funding Plan With Next Recompetition

April 24, 1987

Procedures For Ending IGs Announced

July 10, 1992